At the 2023 American Society of Clinical Oncology Annual Meeting, Dr. Slamon presented results from the NATALEE trial, showing that Kisqali plus an aromatase inhibitor after surgery for early-stage, hormone receptor-positive, HER2-negative breast cancer, reduced recurrence risk by 25% compared to an aromatase inhibitor alone. Listen to the podcast to hear Dr. Slamon explain: why he thought Kisqali could benefit people with early-stage breast cancer the side effects Kisqali can cause what the results mean for people diagnosed with early-stage, hormone receptor-positive disease
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
3ª PARTE | 17 DIC 2025 | EL PARTIDAZO DE COPE
01 Jan 1970
El Partidazo de COPE
13:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
10:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
13:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana